Robert Uger, Chief Scientific Officer at Trillium Therapeutics Inc. (TRIL), sold 584 shares at $15.20 ($9K) on 2021-01-11, disclosed to the SEC on 2021-01-13.
Scheduled sale ($9k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TRIL | SELL | 2021-05-11 | $34K | — | Filing → |
| TRIL | SELL | 2021-04-09 | $39K | — | Filing → |
| TRIL | SELL | 2021-03-15 | $35K | — | Filing → |